Bryan J. Traynor
Bryan J. Traynor | |
|---|---|
| Born | 1969 (age 56–57) Dublin, Ireland |
| Citizenship | Irish-American |
| Education | University College Dublin (MB, BCh, BAO; MD; PhD) Harvard–MIT Program in Health Sciences and Technology (MMSc) |
| Known for | Co-discovery of the C9orf72 hexanucleotide repeat expansion |
| Awards | Breakthrough Prize Potamkin Prize Sheila Essey Award |
| Scientific career | |
| Fields | Neurology Neurogenetics Amyotrophic lateral sclerosis Frontotemporal dementia |
| Workplaces | National Institutes of Health (NIA) Johns Hopkins University |
Bryan J. Traynor is an Irish-American neurologist and neurogeneticist whose work focuses on the genetics of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). He is known for his contributions to the identification of the C9orf72 hexanucleotide repeat expansion as a major genetic cause of ALS and FTD. Traynor has conducted much of his work at the U.S. National Institutes of Health (NIH), where his research has examined genetic mechanisms underlying neurodegenerative disease and their potential clinical implications.
Traynor has received multiple awards recognizing his contributions to ALS and related dementia research, including the 2026 Breakthrough Prize in Life Sciences, the Potamkin Prize for Dementia Research, and the Sheila Essey Award.